3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Cisplatin
315
Radiotherapy
139
Cetuximab
133
pembrolizumab
131
Docetaxel
122
Carboplatin
119
Radiotherapy, Intensity-Modulated
97
Fluorouracil
94
Paclitaxel
92
Nivolumab
64
Gemcitabine
50
toripalimab
46
Radiation
44
Drug Therapy
39
Capecitabine
39
Magnetic Resonance Spectroscopy
38
Surgical Procedures, Operative
33
camrelizumab
31
130-nm albumin-bound paclitaxel
29
apatinib
27
tislelizumab
26
Chemoradiotherapy
26
Specimen Handling
25
Bevacizumab
24
durvalumab
23
Albumin-Bound Paclitaxel
23
nimotuzumab
22
lenvatinib
21
Sorafenib
21
Platinum
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
etelcalcetide hydrochloride
×
Head & Neck
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts